CN1947721A - 表阿霉素缓释制剂的制备方法 - Google Patents
表阿霉素缓释制剂的制备方法 Download PDFInfo
- Publication number
- CN1947721A CN1947721A CNA2006101221859A CN200610122185A CN1947721A CN 1947721 A CN1947721 A CN 1947721A CN A2006101221859 A CNA2006101221859 A CN A2006101221859A CN 200610122185 A CN200610122185 A CN 200610122185A CN 1947721 A CN1947721 A CN 1947721A
- Authority
- CN
- China
- Prior art keywords
- epirubicin
- solution
- slow
- preparation
- polylactic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 title claims abstract description 41
- 229960001904 epirubicin Drugs 0.000 title claims abstract description 41
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 title claims description 40
- 238000000034 method Methods 0.000 title description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 26
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims abstract description 23
- 239000004626 polylactic acid Substances 0.000 claims abstract description 22
- 229920000747 poly(lactic acid) Polymers 0.000 claims abstract description 21
- 238000004108 freeze drying Methods 0.000 claims abstract description 8
- 238000003756 stirring Methods 0.000 claims abstract description 8
- 238000005406 washing Methods 0.000 claims abstract description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 21
- 238000002360 preparation method Methods 0.000 claims description 20
- 239000007788 liquid Substances 0.000 claims description 14
- 239000000047 product Substances 0.000 claims description 7
- 238000000502 dialysis Methods 0.000 claims description 5
- 239000002244 precipitate Substances 0.000 claims description 2
- MWWSFMDVAYGXBV-FGBSZODSSA-N (7s,9s)-7-[(2r,4s,5r,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydron;chloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-FGBSZODSSA-N 0.000 abstract 1
- 239000011806 microball Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 37
- 239000004005 microsphere Substances 0.000 description 26
- 239000003814 drug Substances 0.000 description 16
- 238000009826 distribution Methods 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000002245 particle Substances 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 238000000935 solvent evaporation Methods 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 206010048610 Cardiotoxicity Diseases 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 231100000259 cardiotoxicity Toxicity 0.000 description 2
- 230000007681 cardiovascular toxicity Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 description 1
- 229930195573 Amycin Natural products 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- -1 body Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 230000002687 intercalation Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000002663 nebulization Methods 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
- Biological Depolymerization Polymers (AREA)
Abstract
表阿霉素缓释制剂的制备方法，涉及一种载药高分子微球，尤其是涉及一种载表阿霉素聚乳酸缓释制剂的制备方法。提供一种避免使用表面活性剂，所得载药微球大小均一，表面圆滑，包封率和载药率较高，具有良好的缓释功效的表阿霉素缓释制剂的制备方法。其步骤为：将表阿霉素盐酸盐溶于DMF中，得溶液A，再加入三乙胺得溶液B，再加入聚乳酸得溶液C，再加入水得混浊液，将混浊液转移至透析袋中，并置于水中透析，搅拌，隔1～3h换水，透析后将得到的产物离心，超声，水洗，除去未包埋的表阿霉素，取沉淀物冷冻干燥，得表阿霉素聚乳酸缓释制剂。
Description
技术领域
本发明涉及一种载药高分子微球，尤其是涉及一种载表阿霉素聚乳酸缓释制剂的制备方法。
背景技术
聚乳酸(PLA)因具有良好的生物相容性及生物可降解性，被广泛应用于药物缓释，已成为生物降解医用材料中最受重视的材料之一。目前，聚乳酸载药微球的制备方法主要有相分离法、乳化溶剂挥发法、喷雾法等。其中乳化溶剂挥发法的应用最为广泛。乳化一溶剂挥发法是将聚合物溶解在有机溶剂中，然后，在搅拌下于水溶液中乳化，随着溶剂的挥发，聚合物微球慢慢形成。此类方法在乳化过程中要用到大量表面活性剂，如聚乙烯醇，而此类表面活性剂通常会粘附在微球表面，导致微球的生物降解性能，体内分布、药物释放特性及生物相容性等的改变。(参见文献：1、Lee，S.C，Oh，J.T，Jang，M.H，Chung，S.I.J.Control.Release，1999，59，123；2、Sjostrom，B，Bergenstahl，B，Kronberg，B.J.Pharm.Sci.，1993，82，584；3、Witschi，C，Doelker，E.Eur.J.Pharm.Biopharm，1997，43，215.)。
表阿霉素是抗肿瘤常用化疗药物，其主要作用是直接嵌入DNA碱基对之间，干扰转录过程，阻止mRNA的形成，从而抑制肿瘤细胞的生长，具有一定的抗肿瘤活性，但其对人体也有较强的骨髓抑止及心脏毒性，另外，表阿霉素在高温高湿度下不稳定，药物溶解后在室温下只能保存24h。
发明内容
本发明的目的旨在针对现有的制备表阿霉素缓释制剂的方法中的不足，提供一种避免使用表面活性剂，所得载药微球大小均一，表面圆滑，包封率和载药率较高，具有良好的缓释功效的表阿霉素缓释制剂的制备方法。
本发明的技术方案是采用透析法制备PLA载表阿霉素缓释微球。
本发明的具体步骤如下：
1)将表阿霉素盐酸盐溶于N-N二甲基甲酰胺(DMF)中，得表阿霉素盐酸盐溶液，记为溶液A；
2)在溶液A中加入三乙胺，得溶液B；
3)在溶液B中加入聚乳酸，得溶液C；
4)在溶液C中加入水，得混浊液；
5)将混浊液转移至透析袋中，并将透析袋置于水中透析，同时搅拌，隔1～3h换水；
6)透析4～48h后将步骤5得到的产物离心，超声，水洗，除去未包埋的表阿霉素，取沉淀物冷冻干燥，得表阿霉素聚乳酸缓释制剂。
按质量比N-N二甲基甲酰胺∶水∶表阿霉素盐酸盐∶聚乳酸∶三乙胺＝3000∶(160～12000)∶(0.5～8)∶(5～80)∶(2～4)。聚乳酸的相对分子量最好为(0.5～5)万。透析袋的截留分子量(MWCO)最好为8000～14000。
本发明采用透析法成功制备了粒径分布窄，表面圆滑，表阿霉素在微球内分布均匀，包封率高，且有良好缓释功效的聚乳酸载表阿霉素微球。将表阿霉素制成微球，降低了表阿霉素的心脏毒性以及骨髓抑制等毒性，对肿瘤的治疗有重要意义。制备微球时将表阿霉素与一定量的三乙胺混合，可以显著延长表阿霉素在高湿高温条件下的稳定性，从而保证了载药聚乳酸微球缓释时药物的药效。因没有表面活性剂的参与，微球的生物降解性能，体内分布、药物释放特性及生物相容性等均可得到明显的改善。另外此法操作工艺简单、实施条件温和，易重复。通过改变透析所用溶剂、聚乳酸浓度、表阿霉素浓度和初始加入的水的体积可以调控微球粒径大小、粒径分布，包封率和载药率。
附图说明
图1为本发明实施例1所得微球的SEM图片。
图2为本发明实施例1所得微球的体外释放曲线。在图2中，横坐标为时间(d)，纵坐标为累积释药量(％)。
图3为本发明实施例2所得微球的SEM图片。
图4为本发明实施例3所得微球的SEM图片。
图5为本发明实施例4所得微球的激光共聚焦显微镜断层扫描图。
图6为本发明实施例4所得微球的SEM图片。
图7为本发明实施例5所得微球的SEM图片。
具体实施方式
下面结合实施例对本发明作进一步说明。
实施例1：
(1)将5mg的表阿霉素盐酸盐溶于30ml N-N二甲基甲酰胺(DMF)得溶液A；(2)取10μl三乙胺加入溶液A中得溶液B；(3)称量50mg的聚乳酸(相对分子量为5000)加入溶液B中，得溶液C；(4)在溶液C中加入1.6ml水，得混浊液；(5)将混浊液转移至透析袋中，并将透析袋置于蒸馏水中透析，同时搅拌，隔2h换水；(6)8h后将步骤5得到的产物离心，超声，水洗3次，除去未包埋的表阿霉素，取沉淀冷冻干燥所得样品。所得样品测得包封率为59.6％，载药率为6.8％，通过扫描电镜观察到微球表面圆滑，粒径分布在400nm～700nm，见图1。通过粒度分析测得微球粒径平均大小为589.5nm，多分散度(polydispersity)为0.095。体外释放实验得出这种微球有缓慢释放表阿霉素得功效，药物最终释放可达70％，见图2。
实施例2：
(1)将12mg的表阿霉素盐酸盐溶于18ml N-N二甲基甲酰胺(DMF)得溶液A；(2)取12μl三乙胺加入溶液A中得溶液B；(3)称量60mg的聚乳酸(相对分子量为5000)加入溶液B中，得溶液C；(4)在溶液C中加入2ml纯净水，得混浊液；(5)将混浊液转移至透析袋中(8000～14000)，并将透析袋置于蒸馏水中透析，同时搅拌，隔2h换水；(6)24h后将步骤5得到的产物离心，超声，水洗3次，除去未包埋的表阿霉素，取沉淀冷冻干燥所得样品。所得样品测得包封率为53.6％，载药率为7.4％，扫描电镜观察到微球表面圆滑，粒径分布在200nm～600nm，见图3。通过粒度分析测得微球平均粒径大小为389.7nm，多分散度(polydispersity)为0.086。
实施例3：
(1)将4mg的表阿霉素盐酸盐溶于3ml N-N二甲基甲酰胺(DMF)得溶液A；(2)取2μl三乙胺加入溶液A中得溶液B；(3)称量40mg的聚乳酸(相对分子量为1万)加入溶液B中，得溶液C；(4)在溶液C中加入0.75ml纯净水，得混浊液；(5)将混浊液转移至透析袋中(8000～14000)，并将透析袋置于蒸馏水中透析，同时搅拌，隔2h换水；(5)4h后将步骤5得到的产物离心，超声，水洗3次，除去未包埋的表阿霉素，取沉淀冷冻干燥所得样品。所得样品测得包封率为30.9％，载药率为4.9％，扫描电镜观察到微球表面圆滑，粒径分布在500nm～1200nm，见图4；通过粒度分析测得微球粒径平均大小为863.5nm，多分散度(polydispersity)为0.067。
实施例4：
(1)将8mg的表阿霉素盐酸盐溶于3ml N-N二甲基甲酰胺(DMF)得溶液A；(2)取2μl三乙胺加入溶液A中得溶液B；(3)称量80mg的聚乳酸(相对分子量为1万)加入溶液B中，得溶液C；(4)在溶液C中加入12ml纯净水，得混浊液；(5)将混浊液转移至透析袋中(8000～14000)，并将透析袋置于蒸馏水中透析，同时搅拌，隔2h换水；(5)4h后将步骤5得到的产物离心，超声，水洗3次，除去未包埋的表阿霉素，取沉淀冷冻干燥所得样品。所得样品测得包封率为24.6％，载药率为2.6％，通过激光共聚焦显微镜观察得出表阿霉素在微球内均匀分布，见图5；通过扫描电镜观察到微球大小均一，粒径分布在600nm～900nm，微球表面圆滑，见图6：通过粒度分析测得微球粒径平均大小为768.4nm，多分散度(polydispersity)为0.068。
实施例5：
(1)将12mg的表阿霉素盐酸盐溶于9ml N-N二甲基甲酰胺(DMF)得溶液A；(2)取12μl三乙胺加入溶液A中得溶液B；(3)称量60mg的聚乳酸(相对分子量为5000)加入溶液B中，得溶液C；(4)在溶液C中加入12ml纯净水，得混浊液；(5)将混浊液转移至透析袋中(8000～14000)，并将透析袋置于蒸馏水中透析，同时搅拌，隔2h换水；(5)48h后将步骤5得到的产物离心，超声，水洗3次，除去未包埋的表阿霉素，取沉淀冷冻干燥所得样品。所得样品测得包封率为24.6％，载药率为9.1％，通过扫描电镜观察到微球大小均一，表面圆滑，粒径分布在250nm～470nm，见图7；通过粒度分析测得微球粒径平均大小为313.6nm，多分散度(polydispersity)为0.059。
Claims (4)
1.表阿霉素缓释制剂的制备方法，其特征在于其步骤为：
1)将表阿霉素盐酸盐溶于N-N二甲基甲酰胺中，得表阿霉素盐酸盐溶液，记为溶液A；
2)在溶液A中加入三乙胺，得溶液B；
3)在溶液B中加入聚乳酸，得溶液C；
4)在溶液C中加入水，得混浊液；
5)将混浊液转移至透析袋中，并将透析袋置于水中透析，搅拌，隔1～3h换水；
6)透析4～48h后将步骤5得到的产物离心，超声，水洗，除去未包埋的表阿霉素，取沉淀物冷冻干燥，得表阿霉素聚乳酸缓释制剂。
2.如权利要求1所述的表阿霉素缓释制剂的制备方法，其特征在于按质量比N-N二甲基甲酰胺∶水∶表阿霉素盐酸盐∶聚乳酸∶三乙胺＝3000∶160～12000∶0.5～8∶5～80∶2～4。
3.如权利要求1或2所述的表阿霉素缓释制剂的制备方法，其特征在于聚乳酸的相对分子量为0.5万～5万。
4.如权利要求1所述的表阿霉素缓释制剂的制备方法，其特征在于透析袋的截留分子量为8000～14000。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2006101221859A CN1947721B (zh) | 2006-09-18 | 2006-09-18 | 表阿霉素缓释制剂的制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2006101221859A CN1947721B (zh) | 2006-09-18 | 2006-09-18 | 表阿霉素缓释制剂的制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1947721A true CN1947721A (zh) | 2007-04-18 |
| CN1947721B CN1947721B (zh) | 2011-01-26 |
Family
ID=38017409
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2006101221859A Active CN1947721B (zh) | 2006-09-18 | 2006-09-18 | 表阿霉素缓释制剂的制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1947721B (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102209531B (zh) * | 2008-11-14 | 2014-08-27 | 梨花女子大学校产学协力团 | 高分子微球的制造方法和通过该方法制造的高分子微球 |
| CN108434124A (zh) * | 2018-06-15 | 2018-08-24 | 厦门大学 | 一种表阿霉素ves复合物和制备方法及其应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001248825A1 (en) * | 2000-04-24 | 2001-11-07 | Tanabe Seiyaku Co., Ltd. | Process for producing microsphere |
| CN1582934A (zh) * | 2004-06-14 | 2005-02-23 | 王安训 | 喜树碱衍生物的纳米微粒、制备方法及其药物用途 |
| CN100400032C (zh) * | 2004-09-16 | 2008-07-09 | 同济大学 | 一种油溶性药物缓释微球的制备方法 |
-
2006
- 2006-09-18 CN CN2006101221859A patent/CN1947721B/zh active Active
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102209531B (zh) * | 2008-11-14 | 2014-08-27 | 梨花女子大学校产学协力团 | 高分子微球的制造方法和通过该方法制造的高分子微球 |
| CN108434124A (zh) * | 2018-06-15 | 2018-08-24 | 厦门大学 | 一种表阿霉素ves复合物和制备方法及其应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1947721B (zh) | 2011-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zupančič | Core-shell nanofibers as drug-delivery systems | |
| Abdul Hameed et al. | Electrospun nanofibers for drug delivery applications: Methods and mechanism | |
| US7883723B2 (en) | Water soluble chitosan nanoparticle for delivering an anticancer agent and preparing method thereof | |
| Vijayan et al. | Optimization and charaterization of repaglinide biodegradable polymeric nanoparticle loaded transdermal patchs: In vitro and in vivo studies | |
| KR101862416B1 (ko) | 마이크로입자를 제조하기 위한 에멀전-기반 방법 및 이 방법과 함께 사용하기 위한 워크헤드 조립체 | |
| EP2644191B1 (en) | Nonwoven membrane as a drug delivery system | |
| Shah et al. | Chitosan and carboxymethyl cellulose-based 3D multifunctional bioactive hydrogels loaded with nano-curcumin for synergistic diabetic wound repair | |
| US20100003300A1 (en) | Injectable delivery of microparticles and compositions therefore | |
| CN104136012B (zh) | 制备装载有活性物质的纳米颗粒的方法 | |
| Meng et al. | Tenofovir containing thiolated chitosan core/shell nanofibers: in vitro and in vivo evaluations | |
| JP2007070332A (ja) | 多糖類で機能化された水和ゲル膜を有するナノ粒子とこれを含む徐放型薬物伝達システム及びその製造方法 | |
| Norouzi et al. | Emulsion electrospinning of sodium alginate/poly (ε-caprolactone) core/shell nanofibers for biomedical applications | |
| Yousefi et al. | Polycaprolactone/chitosan core/shell nanofibrous mat fabricated by electrospinning process as carrier for rosuvastatin drug | |
| Stevanović et al. | ROS-inducing potential, influence of different porogens and in vitro degradation of poly (D, L-lactide-co-glycolide)-based material | |
| Priya Dasan et al. | Polymer blend microspheres for controlled drug release: the techniques for preparation and characterization: a review article | |
| Liu et al. | Biodegradable and dissolvable resveratrol nanocrystals non-silicon microneedles for transdermal drug delivery | |
| CN1947721B (zh) | 表阿霉素缓释制剂的制备方法 | |
| Joung et al. | PLGA microparticle-embedded thermosensitive hydrogels for sustained release of hydrophobic drugs | |
| Anjum et al. | Multifunctional electrospun nanofibrous scaffold enriched with alendronate and hydroxyapatite for balancing osteogenic and osteoclast activity to promote bone regeneration | |
| Zhao et al. | Development and optimization of insulin-chitosan nanoparticles | |
| Lee et al. | Thiolate poly (lactic-co-glycolic acid) nanofibers loaded with dexamethasone and ropivacaine show enhanced sustained release in the treatment of neuropathic pain through a local therapy technique | |
| CN115920126A (zh) | 负载植物外泌体的聚羟基脂肪酸酯微球及其制备方法 | |
| CN114748637B (zh) | 苯硼酸修饰型纳晶药物稳定系统及其制备方法和应用 | |
| Ahmady et al. | Alginate carrier as a controlled thymol delivery system: Effect of particle size | |
| WO2011119903A2 (en) | Emulsions for microencapsulation comprising biodegradable surface-active block copolymers as stabilizers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: HISUN HUIRUI PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: XIAMEN UNIVERSITY Effective date: 20140917 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 361005 XIAMEN, FUJIAN PROVINCE TO: 200032 XUHUI, SHANGHAI |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20140917 Address after: 200032, room 10, building 596, block A, No. 1003 middle Longhua Road, Shanghai, Xuhui District Patentee after: HAIZHENGHUI PHARMACEUTICAL CO., LTD. Address before: Xiamen City, Fujian Province, 361005 South Siming Road No. 422 Patentee before: Xiamen University |
|
| DD01 | Delivery of document by public notice | ||
| DD01 | Delivery of document by public notice |
Addressee: HAIZHENGHUI PHARMACEUTICAL CO., LTD. Document name: Notification of Passing Examination on Formalities |
|
| CP03 | Change of name, title or address |
Address after: 311404 2 Hai Zheng Road, Xu Kou Town, Fuyang District, Hangzhou, Zhejiang Patentee after: Hanhui Pharmaceutical Co., Ltd. Address before: Room 1003, 10th floor, Block A, 596 Longhuazhong Road, Xuhui District, Shanghai Patentee before: HAIZHENGHUI PHARMACEUTICAL CO., LTD. |
|
| CP03 | Change of name, title or address |